This presentation wil provide you the latest trends (up to March 2013) on both Global and Asia Pacific OTC markets.
This presentation is in English and Mandarine.
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
This presentation wil provide you the latest trends (up to March 2013) on both Global and Asia Pacific OTC markets.
This presentation is in English and Mandarine.
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Future of the Global Pharmaceutical IndustryTim Opler
Key points in presentation from Torreya Partners.
Despite concerns regarding research productivity and pricing pressure, Torreya is optimistic about the pharma sector. There is huge growth ahead driven by expanding global wealth.
The global pharma sector is going to at least triple in scale between now and 2060.
The pharmaceutical sector is 30% larger than shown by prior data.
New technologies in manufacture, biologics, nucleic acids and implantables will dramatically alter the pharma sector.
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Future of the Global Pharmaceutical IndustryTim Opler
Key points in presentation from Torreya Partners.
Despite concerns regarding research productivity and pricing pressure, Torreya is optimistic about the pharma sector. There is huge growth ahead driven by expanding global wealth.
The global pharma sector is going to at least triple in scale between now and 2060.
The pharmaceutical sector is 30% larger than shown by prior data.
New technologies in manufacture, biologics, nucleic acids and implantables will dramatically alter the pharma sector.
Indian Pharma Market - IPM Overview June 2015Anup Soans
Major Highlights for Month of June 2015:
...................................................................
Indian Pharma Market (IPM) clocked 7928 Crs in June 2015
........................................................................
IPM grew at 14.8% for the month of June 2015
...................................................................................
Companies:
For the month of June 2015, among the top 10, Sun* grew by 27.9% followed by Pfizer at 20.2% & Abbott* at 19.0%
.........................................................................................................
23 companies crossed the growth of IPM for the month of June 2015 among top 50
...............................................................................................
Among the top 50, Wockhardt has the highest growth of 36.2% followed by AstraZeneca at 35.4% & Glenmark at 34.5 %
..................................................................................................
27 Co's showed growths more than 10% among the top 50
............................................................................................
Among the 11-20 ranked, Glenmark has the highest growth of 34.5% followed by Torrent at 28.3% & USV at 27.1%
..................................................................................................
Among the 21-30 ranked, Wockhardt has the highest growth at 36.2% followed by MSD* 31.6% & Unichem at 20.5% & Novo Nordisk at 18.9%
......................................................................................................
Among the 31-40 ranked, AstraZeneca has the highest growth at 35.4% followed by Akumentis at 33.4% & JBCPL at 27.0%
....................................................................................................
Among the 41-50 ranked, Hetero has the highest growth at 21.0% followed by Fourrts at 17.9% & Allergan at 17.8%
..............................................................................................
Among the 51-60 ranked, Boehringer grew at 79.1% followed by Eli Lilly at 39.9% & Troikaa at 38.4%
..............................................................................................
Among the 61-70 ranked, Fresenius Kabi grew at 38.8% followed by RPG at by 36.1% followed by TTK at 26.3%
..............................................
AstraZeneca enters the 500 Cr Club, Hetero 400 Crs, Troikaa 300 Crs, Tablets India 200 Crs on MAT Basis
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Major Highlights for Month of July 2014: IPM clocked 7161 Crs in July 2014
Indian Pharma Market grew at 7.2% for the month of July 2010
For the month of July 2014, among the top 10, Sun Pharma grew by 14.2%, Lupin by 13.2% & Cipla at 9.5%
Macleods grew at 27.9% to be the 10th biggest corporate for the month of July 2014
With the Portfolio of Elder, Torrent is now placed at 16th rank in IPM.
24 co's have crossed the growth of IPM for the month of July 2014 among top 50
Among the top 50 Co's, Akumentis has the highest growth of 49.0% followed by Ajanta at 41.2% & Apex at 40.9%
16 Co's showed double digit growths among the top 50
Among the 11-20 ranked co's Macleods has the highest growth of 27.9% followed by Ipca at 21.2% & Aristo at 16.2%
Among the 51-60 ranked co's, Panacea grows at 36.9% followed by Troikaa at 22.3 & Systopic 20.3%
Among the 61-75 ranked co's, Lincoln grew at 43.7% followed by Corona at 36.3% & Serdia at 19.6%
Indian V/S MNCs:
Indian companies have grown at 9.1% versus 1.5% for MNCs in July 2014
Among the top 50 MNCs, MSD & Janssen grew at 6.9% and Ranbaxy at 5.7%
Under the Non-NLEM category Indian Companies degrew at 11.1% whereas MNCs degrew at 2.5%
DPCO V/s Non DPCO Market:
The DPCO 2013 containing molecules market was at –0.7% whereas the non DPCO market grew by 8.90% resulting in an overall growth of 7.2% for July 2014
NLEM Category showed positive unit growth at 3.2%
The DPCO 2013 portfolio for Pfizer degrew at 16.7%, GSK degrew at 7.9% & Ranbaxy grew by 18.2%.
Source: AIOCD Pharmasofttech AWACS
India pharmacy retail market report -2020 |India Pharmacy Retail MarketKen Research Pvt ltd.
India Pharmacy Retail Market Outlook to 2020 – Growth Driven by Surge in OTC Drugs Sales and Expansion of Online Pharmacies” provides a comprehensive analysis of the various aspects such as market size of the India Pharmacy Retail and Online Pharmacy Retail Market. The report also covers the market segmentation on the basis of organized & unorganized pharmacies, prescribed drugs, OTC drugs & private label products, category of drugs and generic & patented drugs. The report shares the company profile and competitive landscape for major players in the organized pharmacy sector and online pharmacy market.
Pharmacy retail market in India is driven by growth in the pharmaceutical sector, registered revenues of INR ~ billion in FY’2015. With the advent of online pharmacy retailers in the market, the industry is likely to witness a surge in the coming future. The retail pharmacy in the India has escalated at a CAGR of 19.4% from INR ~ billion in FY’2010 to INR ~ billion in FY’2015. The surge in growth is chiefly guided by the escalation in urbanization, increase in household expenditures, increasing smartphone users, need for convenience and rising literacy rate in the country coupled with growing medical awareness.
Indian Pharma Market - Sales Highlights of May 2015Anup Soans
Indian Pharma Market (IPM) - Major Highlights of May 2015
........................................................................................
IPM clocked 7717 Crs in May 2015
IPM grew at 11.0% for the month of May 2015
...............................................................................................
Top IPM Companies:
Among the top 10, Sun grew by 19.9% followed by Cipla at 15.4% & Abbott at 13.2%
............................................................................................
23 companies crossed the growth of IPM in May among top 50
.......................................................................................
In the top 50, Akumentis had the highest growth of 29.1% followed by Glenmark at 28.9% & Torrent at 27.0 %
...........................................................................................
25 Companies grew at more than 10% among the top 50
................................................................................................
Among the 11-20 ranked, Glenmark has the highest growth of 28.9% followed by Torrent at 27.0% & Aristo at 21.7%
...........................................................................................
Among the 21-30 ranked, MSD* had the highest growth at 23.9% followed by Wockhardt 21.2% & Alembic at 15.1%
.....................................................................................................
Among the 31-40 ranked, Akumentis has the highest growth at 29.1% followed by Merck at 21.3% & Bharat Serums at 18.7%
................................................................................................
Among the 41-50 ranked, Allergan has the highest growth at 26.8% followed by Wallace at 11.6% & Apex at 11.5%
.............................................................................
Among the 51-60 ranked, Eli Lilly grew at 34.4% followed by Troikaa at 27.0% & Centaur at 23.7%
.....................................................................................
Among the 61-70 ranked, Boehringer grew at 61.1% followed by Fresenius Kabi grew by 53.9% followed by RPG at 29.6%
..................................................................................
Glenmark enters the 2000 Cr mark, Natco 100 Crs on MAT Basis
.......................................................................................
Indian Vs. MNCs
Indian companies grew at 11.2% Vs. 10.2% for MNCs in May 2015
..................................................................................................
Among the top 50 in MNCs, Allergan grew by 26.8% followed by MSD* at 23.9% & Merck at 21.3%
...................................................................................
Under the Non-NLEM category Indian Companies grew at 4.7% whereas MNCs grew at 6.9%
....................................................................................
DPCO, Non DPCO & Non-Scheduled Para 19 Market:
DPCO containing molecules market grew at
This presentation covers the Introduction to Healthcare & different Products, Role of Pharmaceutical in Healthcare, Drug Details, What a drug is made of ?, Classification of drugs, Product Life Cycle of a Drug, Drug Development Phases, Regulatory Framework & various Regulatory Bodies
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMSHealthRWES
Welcome to the IMS Health Real-World Evidence (RWE) Solutions program of activities at the forthcoming ISPOR 18th Annual European Congress in Milan. We invite you to join us at more than 70 presentations that spotlight exciting innovations and applications of outcomes research and RWE. And please visit us at our booth to learn more about our pioneering efforts including the e360TM technology suite, RWD Catalogue with 1,800+ data sources identified, and the newly launched RWE Dictionary. Full details of our ISPOR schedule can be found in the brochure.
Aarti Drugs (ADL) is a part of well known Aarti group of industries. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also manufactures formulations through its wholly-owned subsidiary- Pinnacle Life Science Private Limited.
The company has a long standing track record in the bulk drugs industry and has been supplying products to demanding domestic and international customers.
Healthcare Services Sector Update - March 2017Duff & Phelps
The S&P Healthcare Services Index decreased 0.9% over the last month, underperforming the S&P 500, which remained flat over the same period. The best performing sectors were Emergency Services (up 12.0%), Care Management / TPA (up 4.9%), and HCIT (up 4.1%). Read the report for more detail on sector activity.
Healthcare Services Sector Update - June 2017Duff & Phelps
The S&P Healthcare Services Index increased 7.2% over the last month, outperforming the S&P 500, which remained relatively flat over the same period. The best performing sectors were Psychiatric Hospitals (up 15.6%), Healthcare Staffing (up 12.9%), and Skilled Nursing (up 12.4%). Read the report for more detail on sector activity.
Healthcare Services Sector Update March 2018Duff & Phelps
Duff & Phelps' Healthcare Services Sector Update March 2018
issue provides details on the best performing healthcare sectors, sector activity and industry trends for this quarter.
Healthcare Services Sector Update - January 2017Duff & Phelps
The S&P Healthcare Services index increased 5.8% over the past month, outperforming the S&P 500, which increased 1.8% over the same period. The best performing sectors were Assisted/Independent Living (up 17.5%), HCIT (up 10.8%) and Emergency Services (up 10.6%).
Healthcare Services Sector Update - October 2016Duff & Phelps
The S&P Healthcare Services Index decreased 7.5% over the past month, underperforming the S&P 500, which remained relatively flat over the same period. The best performing sector was Healthcare Staffing (up 7.5%), which was driven by Blackstone’s announced acquisition of TeamHealth on October 31, 2016.
Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.
India Animal Health Market PPT: Demand, Trends and Business Opportunities 202...IMARC Group
Looking forward, the india animal health market value is projected to reach a strong growth during the forecast period (2022-2027).
More info:- https://www.imarcgroup.com/india-animal-health-market
Healthcare Services Sector Update - February 2018Duff & Phelps
The S&P Healthcare Services Index dipped 4.0% over the last month, which was in line with the S&P 500, which declined 3.9% over the same period. Read more about current healthcare industry report..
Healthcare Services Sector Update - January 2018Duff & Phelps
The S&P Healthcare Services Index increased 8.2% over the last month, outperforming the S&P 500, which increased 5.6% over the same period. The best performing sectors were Acute Care Hospitals (up 13.3%), Distribution (up 10.2%), and Dialysis Services (up 9.3%). Read the report for more detail on sector activity.
Industry Coverage Report on Indian Pharmaceuticals Sector which encapsulates the structure, drivers, key trends, concentration and current scenario. Prepared by me in association with the Alpha Investment & Research Club, FMS Delhi.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
To date, the Indian pharma market has been dominated by the trade/retail segment. This is unlike most mature
markets globally which usually operate in a multi-channeled business model involving
not only trade outlets, but also hospitals, over-the-counter and retail chains. However, in light of the increasing demand for quality care in hospitals, as well as
increased government spending and recent regulatory changes, India is slowly evolving
into a multi-channel market. The most striking aspect of this shifting paradigm is the
increasing dominance of the hospital segment.
The insights driving superior healthcare
outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region to engage in conversations about the forces that are shaping healthcare in Asia - and the strategies necessary to surge ahead of the competition
Growing Pains. China new's realities and the necessity of an informed strateg...QuintilesIMS Asia Pacific
China is a rapidly evolving healthcare market. However companies that take too macroscopic approach to projecting growth, disregarding the more granular trends across drug categories, risk facing a gap between assumed and actual portfolio growth. To address this gap, companies have a variety of options, ranging across levels of difficulty and the degree of transformation necessary.
Download the paper to learn more.
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Understand more about the Awareness, Affordability and Access strategic framework to drive success for global pharma companies engaging with Asian Markets.
While progress has been made in India over the past decade from both public and private sector initiatives, significant challenges persist in providing quality healthcare on an equitable, accessible and affordable basis across all regions and communities, according to a new IMS Institute for Healthcare Informatics study. A 40-45 percent reduction in out-of-pocket expenditures for both outpatient and inpatient treatments can be attained through a holistic approach addressing four critical, interrelated dimensions of healthcare access. Those components are: physical accessibility and the location of healthcare facilities; availability and capacity of needed resources; quality and functionality of service required for patient treatment; and affordability of treatment relative to a patient’s income.
The study – Understanding Healthcare Access in India: What is the Current State? – is the most comprehensive assessment of healthcare access undertaken since 2004 and is based on an extensive survey of nearly 15,000 households covering all socio-economic groups in rural and urban areas across 12 states. Information was gathered on more than 30,000 healthcare system interactions, supplemented by interviews with over 1,000 doctors and experts.
The full report is available at http://www.theimsinstitute.org for downloading.
The top 20 multinational pharmaceutical companies in Asia will see an average of $950 million in sales become at risk in the next 5 years due to the loss of exclusivity of their top brands. How can MNCs survive and thrive in this increasingly genericized era?
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
2. 1
IPM overview
Market Reflection Report March 2015
TSA IPM Trends SSA IPM Trends
IPM was valued at Rs. 90,346 crs and the retail sector was valued at Rs. 76,482 crs as of MAT Mar’15 with CAGR growth of 11%
during the period 2012-15
Anti-infectives, Cardiac and Gastro Intestinal remains the leading therapeutic categories accounting for 36% of IPM
Indian companies continue to drive growth in the market with Sun catapulted to the top of the league, after its merger deal with
Ranbaxy fructified, as forecasted by IMS Health in Jan ‘15
Acute therapies dominates the market constituting 70% of IPM
MonthGrowth%
Value Rs. crs
Growth
SPLY
90,346
80,566
73,096
66,054
7,4646,4145,8615,446
+16%
+12%
2015201420132012
76,482
67,709
61,394
55,577
6,2815,3954,8844,551
+16%
+13%
2015201420132012
MonthMAT
20
15
10
5
0
25
DecNovOctSepAugJulJunMayAprMarFebJan
25
20
0
10
5
15
DecNovOctSepAugJulJunMayAprMarFebJan
2013
2015
2014
3. 2
Top 150 companies snapshot
• Lupin moved up among the top 10 companies as a result of the merger of Ranbaxy with Sun; the market share of
the top 10 companies increased from 40% of IPM in Feb ’15 to 43% in Mar ’15 on MAT and month basis
• The top 150 companies continue to account for 97% of IPM on MAT and month basis
Source: IMS Health TSA, Mar ‘15
IPM value – Rs.7,464 crs (16% Growth)
Month Mar ‘15
IPM value – Rs.90,346 crs (12% Growth)
MAT Mar ‘15
249
494
488
381
830
Value (Rs. Crs)
Rank #101 - 150
Rank #61 - 100
Rank #41 - 60
Rank #31 - 40
Rank #21 - 30
Rank #11 - 20 1,623
Rank #1 - 10 3,193
3
7
7
5
11
22
43
% MS
9
14
18
14
18
21
15
% Gwth Value (Rs. Crs)
3,087
6,029
5,901
4,762
9,976
19,244
38,851
3
7
7
5
11
21
43
% MS
8
12
18
12
11
13
12
% Gwth
Market Reflection Report March 2015
4. 3
Top companies #1-10
TSA: Macleods registered significant growth greater than 20% both on MAT and month basis.
SSA: Intas registered double the growth % of IPM during the month while Macleods and Mankind registered
significant growth greater than 20% both on MAT and month basis Source: IMS Health TSA & SSA, Mar ‘15
250
254
261
269
382
470
618
Value
(Rs. Crs)
Lupin Limited 214
Pfizer 226
Macleods Pharma 248
Alkem
GlaxoSmithKline
Zydus Cadila
Mankind
Cipla
Abbott
Sun
17
11
26
19
10
7
24
19
12
11
% Gwth
2.9
3.0
3.3
3.4
3.4
3.5
3.6
5.1
6.3
8.3
% MS
179
181
204
217
218
220
240
302
401
524
Value
(Rs. Crs)
Intas Pharma
Lupin Limited
GlaxoSmithKline
Macleods Pharma
Zydus Cadila
Alkem
Mankind
Cipla
Abbott
Sun
32
18
11
27
8
21
24
18
11
12
% Gwth
2.8
2.9
3.3
3.5
3.5
3.5
3.8
4.8
6.4
8.3
% MS
Month
Value
(Rs. Crs)
Lupin Limited 2,581
Pfizer 2,745
Macleods Pharma 2,933
GlaxoSmithKline 3,088
Alkem 3,113
Mankind 3,171
Zydus Cadila 3,181
Cipla 4,760
Abbott 5,742
Sun 7,538
15
9
23
5
11
19
3
20
8
10
% Gwth
2.9
3.0
3.3
3.4
3.5
3.5
3.5
5.3
6.4
8.3
% MS
Value
(Rs. Crs)
Lupin Limited 2,173
Pfizer 2,218
GlaxoSmithKline 2,523
Macleods Pharma 2,556
Zydus Cadila 2,667
Alkem 2,717
Mankind 2,825
Cipla 3,777
Abbott 4,974
Sun 6,398
16
8
8
25
4
12
20
16
8
11
% Gwth
2.8
2.9
3.3
3.3
3.5
3.6
3.7
4.9
6.5
8.4
% MS
MAT
SSA
TSA
Market Reflection Report March 2015
5. 4
Top companies #11-20
• TSA –The majority of companies in this bucket posted significant growth greater 20% than during the month
• SSA –Similarly, Dr. Reddys, Aristo, Torrent and Alembic posted strong retail growth greater than 20% during the
month Source: IMS Health TSA & SSA, Mar ‘15
149
167
169
175
176
182
209
Value
(Rs. Crs)
Micro Labs 122
Alembic 125
Glenmark Pharma 147
U S V
Sanofi
Emcure
Dr Reddys Labs
Aristo Pharma
Torrent Pharma
Intas Pharma
12
24
20
14
16
8
28
28
24
33
% Gwth
1.6
1.7
2.0
2.0
2.2
2.3
2.4
2.4
2.4
2.8
% MS
104
113
123
128
135
144
146
156
160
177
Value
(Rs. Crs)
Micro Labs
Alembic
Sanofi
Glenmark Pharma
U S V
Emcure
Dr Reddys Labs
Aristo Pharma
Torrent Pharma
Pfizer
15
24
10
19
15
9
30
28
25
9
% Gwth
1.7
1.8
2.0
2.0
2.2
2.3
2.3
2.5
2.6
2.8
% MS
Value
(Rs. Crs)
Alembic 1,494
Micro Labs 1,517
U S V 1,746
Glenmark Pharma 1,781
Dr Reddys Labs 1,949
Aristo Pharma 2,019
Sanofi 2,061
Emcure 2,126
Torrent Pharma 2,170
Intas Pharma 2,381
14
7
9
19
13
15
5
12
11
21
% Gwth
1.7
1.7
1.9
2.0
2.2
2.2
2.3
2.4
2.4
2.6
% MS
Value
(Rs. Crs)
Micro Labs 1,284
Alembic 1,354
Sanofi 1,544
Glenmark Pharma 1,551
U S V 1,577
Dr Reddys Labs 1,651
Emcure 1,777
Aristo Pharma 1,796
Torrent Pharma 1,902
Intas Pharma 2,037
9
15
11
19
10
17
13
16
12
21
% Gwth
1.7
1.8
2.0
2.0
2.1
2.2
2.3
2.4
2.5
2.7
% MS
SSA
TSA
MonthMAT
Market Reflection Report March 2015
7. 6
Highlights
TSA
Movers & Shakers TSA: Companies
In the month of March’15(in comparison to
Feb’15), among the top 25 companies
Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.28 %.
Aristo Pharma has gained 4 ranks and moved to
13th position.
Glaxosmithkline has gained 3 ranks and moved
to 6th position.
Dr Reddys Labs & USV have gained 2 ranks
and moved to 14th & 17th position respectively.
As per March’15 MAT (in comparison to
Feb’15) among the top 25 companies
Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.34 %.
Companies below Ranbaxy have gained 1 rank
post Sun-Ranbaxy merger.
SSA
Movers & Shakers SSA: Companies
In the month of March-15 (in comparison to
February-15 month), among the TOP 25
companies
Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.34 %.
Alkem & Lupin have gained 3 ranks each &
occupied 5th & 9th position respectively.
Dr Reddys Labs & USV have gained 2 ranks
each & occupied 14th & 16th position
respectively.
Intas gained 1 rank to occupy the 10th position
As per March-15 MAT (in comparison to
February-15 MAT), among the TOP 25
companies
Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.36 %.
Aristo Pharma & Glenmark have gained 2 ranks
each & occupied 13th & 17th position
respectively.
Market Reflection Report March 2015
8. 7
NLEM/Non-NLEM
ValueVolume
NLEM impacted drugs constituted 15% of IPM in value terms with a growth of 10.4% as of MAT Mar ‘15 over same
period last year (SPLY)
The share of the non-NLEM drugs was 76% of IPM in volume terms for the month of Mar’15
Source: IMS Health TSA, Mar ‘15
SPLY Previous month
Mar '14 Mar '15 Value Growth
(%)
Feb '15 Mar '15
Value Growth (%)
Rs. (crs) Rs. (crs) Rs. (crs) Rs. (crs)
NLEM 989.1 1091.9 10.4 1119.2 1091.9 -2.4
Non-NLEM 5424.5 6371.7 17.5 6439.7 6371.7 -1.1
IPM 6413.6 7463.6 16.4 7558.8 7463.6 -1.3
SPLY Previous month
Mar '14 Mar '15
Volume Growth
(% )
Feb '15 Mar '15
Volume Growth
(%)Units (‘000) Units (‘000) Units (‘000) Units (‘000)
NLEM 380800 399972 5.0 406526 399972 -1.6
Non-NLEM 1184052 1298946 9.7 1322253 1298946 -1.8
IPM 1564851 1698918 8.6 1728779 1698918 -1.7
Market Reflection Report March 2015
9. 8
Indian /MNC trends
• Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of
18.6% over Mar’14
• MNCs registered a growth of 10.4% as against the IPM growth of 16.4% during the month
Source: IMS Health TSA, Mar ‘15
0
5
10
15
20
25
Apr ’14
IPM
Mar ’15Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14
% Gwth over same month last year
Jun ’14May ’14 Jul ’14 Aug ’14
MNC
Indian
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
Value (Rs. Crs)
MNC
Apr ’14 Jul ’14 Aug ’14 Sep ’14 Oct ’14 Nov ’14 Dec ’14 Jan ’15 Mar ’15Feb ’15
Indian
IPM
Jun ’14May ’14
MonthGrowthValue
Market Reflection Report March 2015
10. 9
Acute/Chronic trends
Acute therapies continue to dominate the market accounting for 70% of the market during the month
Chronic therapies registered growth of 15%, while acute therapies posted growth of 17% in Mar ‘15
Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 30% during the
month Source: IMS Health TSA, Mar ‘15
5
10
15
20
25
Apr ’14 Mar ’15Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14Aug ’14Jul ’14Jun ’14May ’14
8788
108118
155
Amoxy. & Clav. SolidsFood SupplementsGlim+MetforminDPP4 inhibitors & CombCough Preps Ethical
30.37 20.40 17.63 -5.05 23.03
9
16
19
Franco Indian
Wockhardt Ltd
Glenmark Pharma
19
26
27
U S V
Novartis Intl.
MSD Pharma
10
11
23
Lupin Limited
Sun
U S V
13
14
15
Nutricia Internat
Abbott
Apex
14
14
17
Mankind
Alkem
GlaxoSmithKline
Top5TC4sTop3Cos.inTC4
Growth (%)
Value (Rs.
Crs)
Value (Rs. Crs)
Growth(%)
Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs)
ChronicAcuteIPM
Market Reflection Report March 2015
11. 10
Top 40 brands
Abbott, Alkem and GlaxoSmithKline have the highest number of brands among the top 40 at 5 each
The vaccine Synflorix (GlaxoSmithKline) registered outstanding growth of 83% during the month
Thyronorm (Abbott), Spasmo-Proxyvon + (Wockhardt) and Shelcal (Torrent Pharma) posted impressive growth
greater than 40% in Mar ’15 over the same month last year
22
23
23
23
26
28
38
20
20
21
Value
(Rs. Crs)
Voveran (Novartis Intl.)
Phensedyl Cough (Abbott)
Clavam (Alkem)
Thyronorm (Abbott)
Glycomet-GP (U S V)
Monocef (Aristo Pharma)
Prevenar-13 (Pfizer)
Corex (Pfizer)
Augmentin (GlaxoSmithKline)
Mixtard (Abbott)
29
8
25
47
18
36
38
16
21
11
% Gwth % MS
0.26
0.27
0.28
0.29
0.30
0.31
0.31
0.35
0.38
0.51
14
15
15
15
15
15
16
16
16
17
Value
(Rs. Crs)
Pan (Alkem)
Moxikind-CV (Mankind)
Calpol (GlaxoSmithKline)
Zincovit (Apex)
Becosules (Pfizer)
Zifi (FDC)
Foracort (Cipla)
Shelcal (Torrent Pharma)
Liv-52 (Himalaya Drug)
Alburel (Reliance Lifescie.)
17
28
27
11
13
37
20
40
7
26
% Gwth % MS
0.19
0.20
0.20
0.20
0.20
0.21
0.21
0.21
0.22
0.22
17
18
18
18
18
19
19
19
19
20
Value
(Rs. Crs)
Janumet (MSD Pharma)
Betadine (Win Medicare)
Lantus (Sanofi)
Galvus Met (Novartis Intl.)
Synflorix (GlaxoSmithKline)
Novomix (Abbott)
Panderm+ (Macleods Pharma)
Spasmo-Proxyvon + (Wockhardt)
Dexorange (Franco Indian)
Volini (Sun)
20
8
7
17
83
18
37
45
4
6
% Gwth % MS
0.23
0.24
0.24
0.24
0.24
0.25
0.26
0.26
0.26
0.26
12
13
13
13
13
13
14
14
14
14
Value
(Rs. Crs)
Pan-D (Alkem)
Aciloc (Cadila Pharma)
Taxim (Alkem)
Zinetac (GlaxoSmithKline)
Eltroxin (GlaxoSmithKline)
Azithral (Alembic)
Budecort (Cipla)
Taxim-O (Alkem)
Duphaston (Abbott)
Electral (FDC)
25
13
14
0
10
30
38
18
13
18
% Gwth % MS
0.16
0.17
0.17
0.17
0.17
0.18
0.19
0.19
0.19
0.19
Top1-10Top11-20
Top21-30Top31-40
Source: IMS Health TSA, Mar ‘15
Market Reflection Report March 2015
12. 11
Star Brands of the month
TSA
Movers & Shakers TSA: Products
Among the Top 25 Products as per Mar’15 MAT (in comparison to Feb’15 MAT)
Mixtard is the No 1 brand.
Thyronorm and Voveran has gained 2 ranks each to occupy 6th and 14th position respectively.
Aciloc has gained 4 ranks to occupy 25th position.
Shelcal has gained 1 rank to occupy 23rd position.
Among the Top 25 products as per March’15 month (in comparison to Feb’15 month)
Mixtard is the No 1 brand.
Synflorix has gained 24 ranks to occupy 16th position.
Spasmo-Proxyvon + has gained 6 ranks to occupy 13th position.
Dexorange and Zifi have gained 5 ranks each to occupy 12th and 25th position respectively.
Prevenar-13, Monocef & Alburel have gained 4 ranks each to occupy 4th, 5th and 21st position respectively.
Shelcal has gained 3 ranks each to occupy 23rd position.
Volini has gained 2 ranks to occupy 11th position.
Phensedyl Cough & Voveran have gained 1 rank each to occupy 9th & 10th position respectively.
Market Reflection Report March 2015
13. 12
Gastro Intestinal
1,066
IPM 7,464
774
866
535
589
591
Cardiac
Respiratory
Anti Diabetic
630
Pain / Analgesics
Anti-infectives
Vaccines 178
Others 240
Gynaec. 416
Neuro / CNS 450
Derma 456
Vitamins / Minerals / Nutrients 7
6
2
3
6
6
8
8
8
10
12
14
100
36
11
22
11
15
17
18
15
21
17
13
20
16
0
8
2
-1
-2
2
1
-1
-9
0
-1
-4
-1
Gwth % (SPLY) Gwth% (Prev. Mth)
Therapy trends
• Vaccines continues to record remarkable value growth of 36% as of MAT Mar ’15
• Anti-infectives constitute the largest market share of 14%, with significant growth on MAT basis
Source: IMS Health TSA, Mar ‘15
Value (Rs Crs) MS %
Market Reflection Report March 2015
15. 14
Glossary
Abbreviation Description/Definition
IPM Indian Pharmaceutical Market
MAT Moving Annual Total
CAGR Compound Annual Growth Rate
TSA Total Sales Audit
SSA Secondary Sales Audit
Gwth Growth
MS Market Share
Rs Rupees
NLEM National List of Essential Medicines
SPLY Same Period Late Year
MNC Multi-National Company
DPP Dipeptidyl Peptidase 4
TC Therapeutic Category
Crore / crs 10 million
Market Reflection Report March 2015
16. 15
About IMS Health
World’s leading provider of healthcare consulting, technology, and informatics
Founded in 1954
Operates in over 100 countries; employs 10,000+ people
world wide
Data from 100,000 suppliers and insights of more than 40
billion healthcare transactions
1200+ experts resources, 3000+ service resources and
5000+ clients
Operational in India for more than 11 years, with over 2000
employees with offices in Gurgaon, Mumbai, Delhi &
Bangalore
PUBLIC HEALTH
Policyreformsand advocacy
Enabling evidence based publichealth
decisions
Health infrastructure development
Health resourcesplanning and
allocation
Monitoring &evaluation
Designing and implementation support
Strengthening health caresupply
chain
Enabling TechnologySolutions
Product& Portfolio strategy
Entry& Growth Strategy
Brand and Commercial Strategy
Pricing and marketaccess
Launch and commercial Excellence
Performance management
Transaction AdvisoryServicesand
Due Diligence
Drug salesdatabase(global and local)
Census - Physicians,Chemists,
Hospitals,Doctor, etc
PHARMA & ALLIED HEALTH
Networkexpansion and management
Doctorselection
Pharma &Providerengagement
strategy
Diseasemanagement
Claimsdatabase
Claimsanalytics– benchmarksand
costs
Patientlevel information
Health technologyassessment
PAYERS PROVIDERS
Providerdatabases
Hospital performance transformation
programs
Performance benchmarking
Expansion &Growth strategy
Feasibilityanalysisand businessplan
development
Brownfield hospital acquisition
Financial modeling,funding modalities
and transaction advisory
BI Solutionsforhospitals
OUR SERVICE OFFERINGS
95 process patents
worldwide in life sciences processes
Ranked 2nd Life Science
Technology Vendors for 2013 (IT
Services) by IDC
World’s most admired
companies FORTUNE Magazine
2008 and 2010
PHARMA AND LIFE-SCIENCES